[Recent trend in the research of hyperlipidemia in Japan. Treatment of refractory hyperlipidemia].
Saito
Y
Y
Yoshida
S
S
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001629:Bezafibrate / Q000627:therapeutic use; D001781:Blood Component Removal; D002784:Cholesterol / Q000097:blood; D004359:Drug Therapy, Combination; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D008072:Hyperlipoproteinemia Type I / Q000097:blood / Q000628:therapy*; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D006954:Hyperlipoproteinemia Type V / Q000097:blood / Q000628:therapy*; D006951:Hyperlipoproteinemias / Q000628:therapy*; D009281:Naphthalenes / Q000627:therapeutic use; D017035:Pravastatin; D011341:Probucol / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D009281:Naphthalenes; D014280:Triglycerides; D002784:Cholesterol; D017035:Pravastatin; D011341:Probucol; D001629:Bezafibrate